Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Chemours (CC) EBITDA (2016 - 2025)

Chemours has reported EBITDA over the past 12 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$5.0 million for Q4 2025, down 108.2% from a year ago — trailing twelve months through Dec 2025 was -$63.0 million (down 119.69% YoY), and the annual figure for FY2025 was -$58.0 million, down 363.64%.
  • EBITDA for Q4 2025 was -$5.0 million at Chemours, down from $81.0 million in the prior quarter.
  • Over the last five years, EBITDA for CC hit a ceiling of $304.0 million in Q1 2022 and a floor of -$396.0 million in Q2 2023.
  • Median EBITDA over the past 5 years was $71.0 million (2024), compared with a mean of $73.0 million.
  • Biggest five-year swings in EBITDA: tumbled 282.49% in 2023 and later soared 1116.67% in 2024.
  • Chemours' EBITDA stood at $203.0 million in 2021, then tumbled by 104.43% to -$9.0 million in 2022, then soared by 33.33% to -$6.0 million in 2023, then soared by 1116.67% to $61.0 million in 2024, then tumbled by 108.2% to -$5.0 million in 2025.
  • The last three reported values for EBITDA were -$5.0 million (Q4 2025), $81.0 million (Q3 2025), and -$192.0 million (Q2 2025) per Business Quant data.